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A phase II study was undertaken to determine the safety of combining ﬂutamide with gemcitabine, with response rate being
the primary end point. Twenty-seven patients with histologically proven, previously untreated, unresectable pancreatic
adenocarcinoma received gemcitabine, 1 g m
72 intravenously on days 1, 8 and 15 of a 28 day cycle, and ﬂutamide 250 mg
given orally three times daily. Treatment was halted if there was unacceptable toxicity, or evidence of disease progression.
Toxicity was documented every cycle. Tumour assessment was undertaken after cycles 2 and 4, and thereafter at least every
additional four cycles. One hundred and seventeen cycles of treatment were administered, median four cycles per patient
(range 1–18). Gemcitabine combined with ﬂutamide was well tolerated, with most toxicities being recorded as grade 1 or 2
and only nine treatment cycles associated with grade 3 toxicity. The most frequent toxicity was myelosuppression. One case
of transient jaundice was recorded. The commonest symptomatic toxicity was nausea and vomiting. The response rate was
15% (four partial responses), median survival 6 months and 22% of patients were alive at 1 year. These results suggest
antitumour activity of the combination therapy to be equivalent to single agent gemcitabine.
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Pancreatic cancer is the ﬁfth most common cause of adult death
from malignancy, being responsible for nearly 5% of all cancer
deaths. Unfortunately, to date, over 80% of patients at diagnosis
present with advanced disease not amenable to surgery and their
median life expectancy is around 4 months (Kelly and Benjamin,
1995). Pancreatic adenocarcinoma is both chemo- and radioresis-
tant, with few single agent chemotherapy drugs achieving a
response rate above 10%. In the pivotal prospective multicentre
randomised trial comparing the deoxycitidine analogue, gemcita-
bine (2',2'-diﬂuorodeoxycitidine, Gemzar; Eli Lilly and Co. Ltd),
1gm
72 30 min infusion given weekly, with 5-ﬂuorouracil
(5FU), 600 mg m
72 30 min infusion given weekly, in previously
untreated pancreatic cancer patients (Burris et al, 1997), response
rate, median survival and 1 year survival were 5.4%, 5.65 months
and 18% for the gemcitabine arm, compared with 0%, 4.41 months
and 2% for the 5FU arm. More clinically meaningful effects on
disease-related symptoms (pain control, performance status and
weight gain) were seen in gemcitabine-treated patients, with 24%
achieving a clinical beneﬁt response compared with only 5% of
5FU-treated patients. Despite these limited patient beneﬁts, gemci-
tabine is now internationally accepted as standard systemic
chemotherapy for such patients with unresectable disease.
However, there is a clear need to identify more effective treatments.
Recently, a small single centre randomised placebo-controlled
trial of the oral antiandrogen, ﬂutamide, in unresectable pancreatic
cancer was published (Greenway, 1998). Median survival was 8
months in the ﬂutamide arm and 4 months in the placebo arm.
Excluding patients who progressed within 6 weeks of treatment,
these ﬁgures were 12 and 5 months respectively. These results
support some preclinical data suggesting that testosterone may be
a growth factor for pancreatic cancer. Androgen receptors have
been demonstrated in human pancreatic cancer tissue (Corbishley
et al, 1986), together with the steroid synthetic enzymes, aromatase
and 5areductase (Iqbal et al, 1983). In addition, patients with
pancreatic cancer appear to have low serum testosterone concentra-
tions (Greenway et al, 1983). Finally, testosterone has been shown
to promote the growth of human pancreatic adenocarcinoma xeno-
grafts grown in nude mice, while an antiandrogen inhibited this
effect (Greenway et al, 1982). Greenway’s trial of 49 patients has
been criticised for its small size and histological evidence of the
disease was obtained in only 35% of cases. Even so, the suggestion
that androgen receptor blockade may signiﬁcantly improve survival
of pancreatic cancer patients warrants further testing. Furthermore,
the potential to combine ﬂutamide with gemcitabine is attractive,
since each single agent has a side effect proﬁle acceptable for
pancreatic cancer patients who are frequently elderly, frail and
plagued with disease-related symptoms. We therefore undertook a
phase II study to evaluate the combination regimen of gemcitabine
and ﬂutamide for safety, tolerability and efﬁcacy.
PATIENTS AND METHODS
Patient eligibility
The eligibility criteria were histological or cytological diagnosis of
previously untreated, unresectable (locally advanced or metastatic)
pancreatic adenocarcinoma. Patients with previously resected
disease who had received adjuvant therapy could be entered if
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previous therapy. Measurable disease was required, deﬁned as
evidence of any tumour mass which could be measured bidimen-
sionally either clinically or radiologically. Baseline CT scans were
performed within 4 weeks prior to commencing treatment. Patients
had to be at least 18 years of age, with Eastern Cooperative Oncol-
ogy Group performance status (PS) 42. Laboratory parameters
were as follows: Hb 510 g dl
71, platelets5100000 mm
73, ANC
51500 mm
3; bilirubin 51.36ULN, Alk phos 52.56ULN, trans-
aminases 52.56ULN; serum Creatinine 51.56ULN. Patients
could be entered beyond 7 days after major surgery or 3 days after
laparoscopy. All patients gave written informed consent and the
study was approved by the local research ethics committees of
the three participating UK centres: Addenbrooke’s Oncology
Centre, Cambridge, the Churchill Hospital, Oxford, and the
Hammersmith Hospital, London.
Systemic therapy
Gemcitabine was administered as a 30 min infusion, 1 g m
72
weekly on days 1, 8 and 15, for 3 consecutive weeks, on a 4 week
cycle. Flutamide was commenced on day 1 and taken orally 250 mg
three times daily. Toxicity was assessed using the National Cancer
Institute common toxicity criteria. Gemcitabine was halted if grade
3 or more nonhepatic toxicity occurred, and recommenced on
recovery at 25% reduced dose. Treatment was halted for grade 2
or more liver toxicity. On recovery to grade 41, gemcitabine
was restarted at full dose, but ﬂutamide was reduced to 250 mg
twice daily in the case of grade 2 liver toxicity and omitted alto-
gether in the case of grade 3 liver toxicity.
The initial study treatment period was deﬁned as four cycles in
the ﬁrst instance. Patients completing cycle 4 with stable or
responding disease and without signiﬁcant side effects were allowed
to continue treatment if they wished. Treatment was discontinued
if there was unacceptable toxicity, evidence of disease progression,
at patient request, or if considered appropriate for any other reason
by the patient’s doctor.
Study parameters
Physical examinations, PS, weight, blood count, renal and liver
function tests were measured at baseline and on days 1, 8 and
15 of every 4 week cycle. Serum CA19.9 was measured at baseline
and if raised, was repeated every 4 weeks. Baseline serum testoster-
one was also measured. Tumour assessment for measurable disease
was performed within 4 weeks of commencing treatment. This was
repeated after cycle 2 and 4 and thereafter, at least every four
cycles. An initial chest X-ray was performed and repeated when
the patient came off study.
Standard WHO criteria were used to assess tumour response.
Complete response (CR) was deﬁned as complete disappearance
of all known disease determined by two observations not less than
4 weeks apart. Partial response (PR) was deﬁned as a decrease of
50% or more in the sum of the products of the two maximum
perpendicular diameters of assessable disease for at least 4 weeks,
with no appearance of new lesions or progression of any lesion.
Stable disease (SD) was deﬁned as a less than 50% decrease or a
less than 25% increase in the sum of the products of the two maxi-
mum perpendicular diameters of assessable disease. Progressive
disease (PD) was deﬁned as a 25% or more increase in the sum
of the products of the two maximum perpendicular diameters of
assessable disease or the development of any new lesions.
Statistical considerations
Using the method described by Gehan (1961), an initial cohort of
14 patients were recruited. Further patients were recruited so that
the standard error of the observed response rate would be less than
or equal to 0.01. This ensured that if the treatment was active in
20% or more patients, the chance of erroneously rejecting it after
the ﬁrst 14 patients was 0.044. Any patient failing to be assessed for
tumour response after cycle 2 required an additional patient to be
recruited to the study. The time to treatment failure was deﬁned as
the time from start of treatment until disease progression was ﬁrst
detected or the patient went off study due to clinical deterioration
in the absence of tumour measurements. Overall survival was
measured from the start of treatment until death from any cause.
RESULTS
Patient characteristics
From March 1999 to July 2000, 27 patients were recruited at three
UK centres. Their characteristics are listed in Table 1. All patients
had histological conﬁrmation of pancreatic adenocarcinoma.
Twenty-four patients presented with locally advanced disease or
metastatic tumours. Three patients had recurrence after primary
resection, of whom two had received adjuvant chemoradiotherapy
as part of the ESPAC 1 trial (Neoptolemos et al, 2001). At the time
of censorship (1st January 2002), two patients remained alive at 95
and 134 weeks.
Objective tumour responses
In the ﬁrst cohort of 14 patients, four objective responses were
recorded: three radiological partial responses (PRs) and one clinical
PR. A further 13 patients were recruited, of whom three progressed
within 6 weeks of treatment and 10 were assessable for response on
completion of cycle 2. For the whole study population (n=27), the
objective response rate was 15% (4 PRs). Of the remaining
patients, 13 (48%) had stable disease of duration ranging between
14 and 76.3 weeks, with median 35.3 weeks. Ten (37%) patients
had progressive disease documented at the ﬁrst assessment.
The objective PRs occurred in two patients with locally
advanced and two patients with disseminated disease, involving
the liver in one case and left supraclavicular and axillary lympha-
denopathy in the other. Responses were documented after cycle 2
in three cases and cycle 4 in one case. These responses were
sustained for 6, 8, 27 and 16 weeks, respectively.
Serum testosterone measurements were recorded for only 60%
of the study population. In 14 cases, testosterone was within the
normal range and in only two cases was it below the lower limit
of normal. There was no correlation of serum testosterone with
disease stage or treatment outcome.
In this study, formal quality of life assessment was not underta-
ken, but patients were weighed and their PS determined prior to
commencing each cycle of therapy. Response to treatment did
not have any beneﬁt to patients in terms of gain or maintenance
of weight. However, patients who responded or whose disease
remained stable maintained their PS for a statistically signiﬁcantly
longer period than those who progressed (P=0.046, paired
student’s t-test).
Survival
The median time to disease progression for all 27 patients entered
into this study was 18.1 weeks (range 1 to 76 weeks). To date, two
patients remain alive and the median survival was 24.5 weeks
(range 4 to 134 weeks), with 22% patients alive at 1 year.
Toxicity
All patients were evaluated for toxicity. The median number of
cycles of combination therapy received was 4, with range 1–18.
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However, haematological grade 3 toxicity was documented on ﬁve
occasions, comprising neutropenia in three cases and anaemia in
two cases. Thrombocytopenia was only ever documented as grade
1 or 2 and occurred on ﬁve occasions. One case of grade 3 liver
toxicity (jaundice) occurred, which appeared to resolve on stop-
ping ﬂutamide. Three cases of symptomatic grade 3 toxicity were
documented, comprising nausea and vomiting in two cases and
skin rash in one case. The most frequently documented sympto-
matic grade 1/2 toxicities were fatigue (11 cases), nausea and
vomiting (nine cases) and diarrhoea (ﬁve cases).
Sixteen patients had no modiﬁcation of their treatment doses
while on study. Modiﬁcations were made because of toxicity attri-
butable to gemcitabine in eight patients and to ﬂutamide in three
patients. Reasons given for gemcitabine modiﬁcation were haema-
tological toxicity or severe skin rash, requiring three patients to
stop gemcitabine treatment entirely. Flutamide was modiﬁed due
to hot ﬂushes or nausea, and in one patient who became jaundiced
after two cycles of treatment, ﬂutamide was omitted. Three male
patients reported breast tenderness which was not considered
severe enough to require treatment modiﬁcation. No treatment
related deaths were recorded.
DISCUSSION
Pancreatic adenocarcinoma is known to be highly resistant to
systemic therapy. The most effective single agent proven in
randomised trials for treating advanced disease is the nucleoside
antimetabolite, gemcitabine, but even with this treatment, bene-
ﬁts to patients are very limited. This trial was designed to
evaluate the novel combination of gemcitabine and the antian-
drogen, ﬂutamide. On a practical basis, a well tolerated
hormonal therapy would seem an attractive option in this group
of highly symptomatic patients. However, ﬂutamide can induce
liver damage, as evidenced by transaminitis, cholestatic jaundice,
liver necrosis, encephalopathy and, rarely, liver failure leading to
death. Since many patients with pancreatic cancer have disease-
related liver dysfunction, the concern was raised that patients
entered into this study might be put at greater risk of ﬂuta-
mide-induced liver damage. In the randomised placebo-
controlled trial of ﬂutamide in advanced pancreatic cancer
patients, ﬂutamide was administered at a standard dose of
250 mg three times daily and no cases of liver toxicity were
reported. Furthermore, in our own institution, a group of 26
patients with radiological evidence of advanced pancreatic cancer
but without histological or cytological conﬁrmation of disease
patients were offered treatment with single agent ﬂutamide. In
this group, no liver-related side effects were reported (Shaw et
al, 2000). The results of this study demonstrate that gemcitabine
can be safely combined with ﬂutamide in patients with advanced
pancreatic adenocarcinoma. Few grade 3 and no grade 4, life
threatening, toxicities were recorded. In a single patient who
became jaundiced shortly after starting combination treatment,
omission of ﬂutamide led to resolution of liver blood tests and
the patient was able to continue treatment with gemcitabine
alone. 60% of patients were able to tolerate full doses of treat-
ment without signiﬁcant toxicity. Of those whose treatment
was modiﬁed, the majority required dose reduction of gemcita-
bine for reasons predicted by the known side effect proﬁle of
this drug. There was no indication that combination therapy
potentiated risk of toxicity from either drug.
The response rate associated with this treatment combination
was 15%. This and the median survival of 6 months equate well
with other phase II study data becoming available for gemcita-
bine-based combination regimens (Louvet et al, 2002), although
many of these cytotoxic regimens are associated with more drug-
related toxicity than described in this study.
In conclusion, it appears that gemcitabine may be safely
combined with ﬂutamide. The combination regimen appears to
be at least as effective as, although probably not superior to single
agent gemcitabine. Although testosterone was not measured in all
study patients, the data does not support a previous report suggest-
ing that all pancreatic cancer patients have low serum testosterone
concentrations (Greenway et al, 1983). Further studies would be
required to identify an antitumour effect of ﬂutamide before
further clinical trials in pancreatic cancer could be justiﬁed.
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Table 1 Patient characteristics
Number of patients 27
Male 17 (63%)
Female 10 (37%)
Age (years)
Median 58
Range 36–73
PS
0 10 (37%)
1 11 (41%)
2 6 (22%)
Disease stage
III 10 (37%)
IVA 4 (15%)
IVB 13 (48%)
Liver metastases 12 (45%)
Table 2 Summary of toxicities experienced by patients, recorded for
each cycle of treatment
Grade 1/2 Grade 3
Toxicity No. cycles (%) No. cycles (%)
Fatigue 11 41 –
Nausea/vomiting 9 33 2 7
Diarrhoea 5 19 –
Constipation 3 11 –
Skin rash 3 11 1 4
Mucositis 3 11 –
Breast tenderness 3 11 –
Fever 2 7 –
Infection 2 7 –
Hot ﬂushes 1 4 –
Peripheral neuropathy 1 4 –
Alopecia 1 4 –
Deep vein thrombosis 1 4 –
Anaemia 9 33 2 7
Thrombocytopenia 5 19 –
Neutropenia 2 7 3 11
Liver toxicity – 1 4
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